At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
Buparlisibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
In Brief
A Phase 2 clinical trial evaluating Buparlisib for Chronic Lymphocytic Leukemia. Completed, enrolled 14 participants across 6 sites.
Detailed Summary
The purpose of this study is to find out what effects a new drug, buparlisib, has on chronic lymphocytic leukemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukemia
CountriesCanada
CollaboratorsNovartis
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartApr 2015
Primary CompletionNov 2018
Study CompletionApr 2020
TodayJul 2026
First PostedJan 19, 2015
Enrollment StartApr 27, 2015
Primary CompletionNov 21, 2018
Study CompletionApr 28, 2020
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 11.5 years ago
Interventions
Buparlisibdrug